Welcome to our dedicated page for Veru SEC filings (Ticker: VERU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
It’s not easy to track how enobosarm milestones or FC2 royalty streams alter Veru’s numbers when the company’s 300-page 10-K hides each detail in dense scientific language. Add frequent 8-K pipeline updates and Form 4 trades by clinical advisers, and information overload sets in. That’s why Veru SEC filings explained simply matters.
Stock Titan’s AI reads every Veru quarterly earnings report 10-Q filing, each 8-K material event, and flags the passages that answer questions like “How much cash remains for Phase 3 trials?” or “Which executives exercised options?” Our platform delivers real-time alerts on Veru insider trading Form 4 transactions, so you see Veru Form 4 insider transactions real-time while the market is still reacting. Interactive dashboards pair raw exhibits with concise AI notes, turning understanding Veru SEC documents with AI into a two-minute task.
- Veru annual report 10-K simplified – pipeline timelines, risk factors and product revenue
- Veru proxy statement executive compensation – compare option grants to performance goals
- Veru earnings report filing analysis – quarter-over-quarter R&D spend and cash-burn trends
- Veru executive stock transactions Form 4 – filter by officer, date or drug-program milestone
Whether you’re monitoring sabizabulin’s cardiovascular study or checking if directors bought shares ahead of a trial read-out, our AI-powered summaries, expert context and instant EDGAR feeds give you the full filing set in one place. No more scrolling through footnotes—just actionable insights, updated the moment Veru files, with Veru 8-K material events explained in plain English.
Veru Inc. (VERU) filed an 8-K disclosing results from its 25 July 2025 special shareholder meeting.
- Reverse stock split: Shareholders approved an amendment authorising the Board to implement a reverse split at any ratio between 1-for-2 and 1-for-20. Votes: 98,869,209 FOR, 7,080,957 AGAINST, 1,013,920 ABSTAIN; 0 broker non-votes.
- Adjournment proposal: Also approved with 100,083,638 FOR, 6,212,862 AGAINST, 667,586 ABSTAIN.
Out of 146,583,920 eligible shares, about 106.9 million (≈73%) were voted. No other matters were considered.
FAQ
What is the current stock price of Veru (VERU)?
What is the market cap of Veru (VERU)?
What core therapeutic areas does Veru Inc. focus on?
What is enobosarm and how is it used?
How does Veru ensure the safety of its clinical programs?
What distinguishes Veru’s approach to weight management therapies?
Does Veru have a global market presence?
What role does sabizabulin play in Veru’s portfolio?
How does Veru communicate its clinical progress to investors?
How does Veru embody the principles of E-E-A-T?
